For patient information click here
WikiDoc Resources for Prader-Willi syndrome
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us  to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Prader-Willi syndrome (abbreviated PWS) is a genetic disorder, in which seven genes (or some subset thereof) on chromosome 15 are missing or unexpressed (chromosome 15q partial deletion) on the paternal chromosome. It was first described in 1956 by Andrea Prader, Heinrich Willi, Alexis Labhart, Andrew Ziegler, and Guido Fanconi of Switzerland. The incidence of PWS is between 1 in 12,000 and 1 in 15,000 live births. The distinction of chromosome by parental origin is due to imprinting and PWS has the sister syndrome Angelman Syndrome that affects maternally imprinted genes in the region.
Traditionally, PWS was diagnosed by clinical presentation. Currently, the syndrome is diagnosed through genetic testing, and is recommended for newborns with pronounced hypotonia. Early diagnosis of PWS allows for early intervention as well as the early prescription of growth hormone. Daily recombinant growth hormone (GH) injections are indicated for children with PWS. GH supports linear growth and increased muscle mass, and may lessen food preoccupation and weight gain.
Clinical Features And Signs
Holm et al (1993) describe the following features and signs as pretest indicators of PWS, although not all will be present.
- Reduced foetal movement
- Frequent abnormal foetal position
- Often breach or caesarian births
- Feeding difficulties (due to poor muscle tone affecting sucking reflex)
- Difficulties establishing respiration
- Failure to thrive (continued feeding difficulties)
- Delayed milestones/intellectual delay
- Excessive sleeping
- Scoliosis (often not detected at birth)
- Speech delay
- Poor physical coordination
- Hyperphagia (over-eating from age 2 - 4 years. Note change from feeding difficulties in infancy)
- Excessive weight gain
- Delayed puberty
- Short stature
- Infertility (males and females)
- Sparse pubic hair
- Learning disabilities/borderline intellectual functioning (but some cases of average intelligence)
- Proneness to diabetes mellitus
General physical appearance (adults)
- Prominent nasal bridge
- Small hands and feet
- Soft skin, which is easily bruised
- Excess fat, especially in the central portion of the body
- High, narrow forehead
- Almond shaped eyes with thin, down-turned lips
- Light skin and hair relative to other family members
- Lack of complete sexual development
- Always picking at their skin
- Delayed motor development
PWS is caused by the deletion of the paternal copies of the imprinted SNRPN gene and necdin gene on chromosome 15 located in the region 15q11-13 . This so-called PWS/AS region may be lost by one of several genetic mechanisms which, in the majority of instances occurs through chance mutation. Other less common mechanisms include; uniparental disomy, sporadic mutations, chromosome translocations, and gene deletions. Due to imprinting, the maternally inherited copies of these genes are virtually silent, only the paternal copies of the genes are expressed. PWS results from the loss of paternal copies of this region. Deletion of the same region on the maternal chromosome causes Angelman syndrome (AS). PWS and AS represent the first reported instances of imprinting disorders in humans.
The risk to the sibling of an affected child of having PWS depends upon the genetic mechanism which caused the disorder. The risk to siblings is <1% if the affected child has a gene deletion or uniparental disomy, up to 50% if the affected child has a mutation of the imprinting control region, and up to 25% if a parental chromosomal translocation is present. Prenatal testing is possible for any of the known genetic mechanisms.
Individuals with PWS are at risk of learning and attention difficulties. Curfs and Frym (1992) conducted research into the varying degrees of learning disability found in Prader Willi Syndrome (PWS). Their results were as follows:
- 5%...IQ above 85 (Average to low average intelligence)
- 27%..IQ 70 - 85 (Borderline intellectual functioning)
- 34%..IQ 50 - 70 (Mild intellectual disability)
- 27%..IQ 35 - 50 (Moderate intellectual disability)
- 5%...IQ 20 - 35 (Severe intellectual disability)
- <1%..IQ <20 (Profound intellectual disability)
Cassidy found that 40% of individuals with PWS have borderline/low average intelligence, a figure higher than that found in Curfs and Frym's study (32%). However, both studies suggest that most individuals (50 - 65%) fall within the the mild/borderline/low average intelligence range.
Children with PWS show an unusual cognitive profile. They are often strong in visual organisation and perception, including reading and vocabulary, but their spoken language (sometimes affected by hypernasality) is generally poorer than their comprehension. A marked skill in completing jigsaw puzzles has been noted.
Auditory information processing and sequential processing are relatively poor, as are arithmetic and writing skills, visual and auditory short term memory and auditory attention span. These sometimes improve with age, but deficits in these areas remain throughout adulthood.
Prader-Willi Syndrome is also frequently associated with an extreme and insatiable appetite, often resulting in morbid, and in some cases life-threatening, obesity. There is currently no consensus as to the cause for this particular symptom, although genetic abnormalities in chromosome 15 disrupt the normal functioning of the hypothalamus (Cassidy, 1997). Given that the hypothalamus regulates many basic processes, including appetite, there may well be a link. However, no organic defect of the hypothalamus has been discovered on post mortem investigation.
There are several aspects of PWS that support the concept of growth hormone deficiency in individuals with PWS. Specifically, individuals with PWS have short stature, are obese with abnormal body composition, have reduced fat free mass (FFM), have reduced LBM and total energy expenditure, and have decreased bone density.
PWS is characterized by hypogonadism. This is manifested as undescended testes in males and benign premature adrenarche in females. Testes may descend with time or can be managed with surgery or testosterone replacement. Adrenarche may be treated with hormone replacement therapy.
PWS should be considered when presented with a hypotonic (floppy) newborn. Accurate consensus clinical diagnostic criteria exist, but the mainstay of diagnosis is genetic testing, specifically DNA-based methylation testing to detect the absence of the paternally contributed Prader-Willi syndrome/Angelman syndrome (PWS/AS) region on chromosome 15q11-q13. Such testing detects over 97% of patients. Methylation-specific testing is important to confirm the diagnosis of PWS in all individuals, but especially those who are too young to manifest sufficient features to make the diagnosis on clinical grounds or in those individuals who have atypical findings.
Prader-Willi Syndrome has no cure. However, several treatments are in place to lessen the condition's symptoms. Growth hormone replacement therapy improves body composition and increases linear height. During infancy, subjects should undergo therapies to improve muscle tone. Speech and occupational therapy are also indicated. During the school years, children benefit from a highly structured learning environment as well as extra help. Throughout their lives, the subject's food should literally be kept under lock and key, since the largest problem associated with the syndrome is severe obesity.
- synd/1836 at Who Named It
- Curfs L.M.G. and Fryns J.P. (1992) Prader-Willi syndrome: a review with special attention to the cognitive and behavioral profile. Birth Defects: Original Article Series 28:99–104
- Cassidy S.B. (1997) Prader Willi Syndrome. Journal of Medical Genetics 34:917-23.
- Udwin O. PWS Update. CaF Directory of Specific Conditions and Rare Syndromes. (1998) 5th Edition.
- Holm V.A., Cassidy S.B., Butler M.G., Hanchett, J.M., Greenswag, L.R., Whitman, B.Y. and Greenberg, F. (1993) Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 91(2): 398-402
| group5 = Clinical Trials Involving Prader-Willi syndrome | list5 = Ongoing Trials on Prader-Willi syndrome at Clinical Trials.gov • Trial results on Prader-Willi syndrome • Clinical Trials on Prader-Willi syndrome at Google
| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Prader-Willi syndrome | list6 = US National Guidelines Clearinghouse on Prader-Willi syndrome • NICE Guidance on Prader-Willi syndrome • NHS PRODIGY Guidance • FDA on Prader-Willi syndrome • CDC on Prader-Willi syndrome
| group7 = Textbook Information on Prader-Willi syndrome | list7 = Books and Textbook Information on Prader-Willi syndrome
| group8 = Pharmacology Resources on Prader-Willi syndrome | list8 = AND (Dose)}} Dosing of Prader-Willi syndrome • AND (drug interactions)}} Drug interactions with Prader-Willi syndrome • AND (side effects)}} Side effects of Prader-Willi syndrome • AND (Allergy)}} Allergic reactions to Prader-Willi syndrome • AND (overdose)}} Overdose information on Prader-Willi syndrome • AND (carcinogenicity)}} Carcinogenicity information on Prader-Willi syndrome • AND (pregnancy)}} Prader-Willi syndrome in pregnancy • AND (pharmacokinetics)}} Pharmacokinetics of Prader-Willi syndrome •
| group9 = Genetics, Pharmacogenomics, and Proteinomics of Prader-Willi syndrome | list9 = AND (pharmacogenomics)}} Genetics of Prader-Willi syndrome • AND (pharmacogenomics)}} Pharmacogenomics of Prader-Willi syndrome • AND (proteomics)}} Proteomics of Prader-Willi syndrome
| group11 = Commentary on Prader-Willi syndrome | list11 = Blogs on Prader-Willi syndrome
| group12 = Patient Resources on Prader-Willi syndrome | list12 = Patient resources on Prader-Willi syndrome • Discussion groups on Prader-Willi syndrome • Patient Handouts on Prader-Willi syndrome • Directions to Hospitals Treating Prader-Willi syndrome • Risk calculators and risk factors for Prader-Willi syndrome
| group13 = Healthcare Provider Resources on Prader-Willi syndrome | list13 = Symptoms of Prader-Willi syndrome • Causes & Risk Factors for Prader-Willi syndrome • Diagnostic studies for Prader-Willi syndrome • Treatment of Prader-Willi syndrome
| group14 = Continuing Medical Education (CME) Programs on Prader-Willi syndrome | list14 = CME Programs on Prader-Willi syndrome
| group17 = Informatics Resources on Prader-Willi syndrome | list17 = List of terms related to Prader-Willi syndrome